Hydroxypropyl cellulose (HPC) is an ether of cellulose where some of the hydroxyl groups of the cellulose have been hydroxypropylated. Hydroxypropyl cellulose is used as an excipient, and topical ophthalmic protectant and lubricant. Hydroxypropyl cellulose, manufactured by Aton Pharma, is a formulation of HPC used for artificial tears. It is used to treat medical conditions characterized by insufficient tear production such as keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure, and neuroparalytic keratitis. HPC is also used as a lubricant for artificial eyes. Hydroxypropyl cellulose acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. Hydroxypropyl cellulose usually reduces the signs and symptoms resulting from moderate to severe dry eye syndromes, such as conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness, and blurred and cloudy vision. Progression visual deterioration which occurs in some patients may be retarded, halted, or sometimes reversed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: the precorneal tear film |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LACRISERT Approved UseLACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions.
LACRISERT is also indicated for patients with:
Exposure keratitis
Decreased corneal sensitivity
Recurrent corneal erosions Launch Date1981 |
|||
Primary | LACRISERT Approved UseLACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions.
LACRISERT is also indicated for patients with:
Exposure keratitis
Decreased corneal sensitivity
Recurrent corneal erosions Launch Date1981 |
|||
Primary | LACRISERT Approved UseLACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions.
LACRISERT is also indicated for patients with:
Exposure keratitis
Decreased corneal sensitivity
Recurrent corneal erosions Launch Date1981 |
Sample Use Guides
One LACRISERT ophthalmic insert (5mg/insert) in each eye once daily
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12622396
Polymer solutions were prepared incrementally, increasing polymer (HPC) concentration by 0.5% per increment (w/v) between 1.0% and 5.0%. A stock solution containing 1 M MES and 0.5 M TRIS (pH 6.1) was prepared and utilized for all buffers throughout the experiments.
Substance Class |
Polymer
Created
by
admin
on
Edited
Sat Dec 16 03:08:21 GMT 2023
by
admin
on
Sat Dec 16 03:08:21 GMT 2023
|
Record UNII |
RFW2ET671P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175535
Created by
admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RFW2ET671P
Created by
admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
|
PRIMARY | |||
|
9004-64-2
Created by
admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
|
GENERIC (FAMILY) | |||
|
27291
Created by
admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
|
ALTERNATIVE | RxNorm | ||
|
2048727
Created by
admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
|
ALTERNATIVE | |||
|
1811461
Created by
admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
|
PRIMARY | |||
|
RFW2ET671P
Created by
admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
|
PRIMARY | |||
|
C29139
Created by
admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
|
PRIMARY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER AVERAGE | CHEMICAL |
|
||||
MOL_WEIGHT:WEIGHT AVERAGE | CHEMICAL |
|
||||
DEGREE OF SUBSTITUTION | CHEMICAL |
|
HYDROXYPROPYL FRAGMENT
(not present in database)
|
|
||
MOLAR SUBSTITUTION | CHEMICAL |
|
HYDROXYPROPYL FRAGMENT
(not present in database)
|
|
||